Citigroup Maintains Buy on ProKidney, Lowers Price Target to $8
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsPrice Target
Citigroup analyst Yigal Nochomovitz maintains ProKidney (NASDAQ:PROK) with a Buy and lowers the price target from $10 to $8.
Citigroup analyst Yigal Nochomovitz maintains ProKidney (NASDAQ:PROK) with a Buy and lowers the price target from $10 to $8.